St. Alphonsus Health System
Print    Email
Decrease (-) Restore Default Increase (+)

Research Opportunities

Title   Evaluation of Varenicline (CHANTIX®) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial
Description   Varenicline (CHANTIX®) is a medication used as an aid to help people stop smoking. Although it has been shown that varenicline can help healthy people quit smoking, researchers would like to determine if it is as effective in those that have suffered a heart attack. To measure the efficacy of varenicline and any side effects, participants will be in one of two possible groups. The control group will recieve placebo or sugar pill, and the other will be given CHANTIX®.
IRB Number   unknown
Treatment   Cardiovascular
Inclusion/Notes  

Adult smokers who regularly smoke more than 10 cigarettes per day and have suffered an ACS requiring hospitalization and are motivated to quit smoking are eligible to participate in this study. More information on Cardiovascular Research can be found here.

Status   Pending
Principal Name   J. Antonio G. Lopez, MD
Fax   (208) 367-7074
Current Trial Type   Randomized, double blind, placebo controlled
Phone   (208) 367-8880

©

 2014  

Saint Alphonsus Health System  |  1055 North Curtis Road  Boise, ID 83706  |  208-367-2121

   Facebook       Twitter       YouTube